ID   NTUB1
AC   CVCL_RW29
DR   ChEMBL-Cells; CHEMBL4651373
DR   PubChem_Cell_line; CVCL_RW29
DR   Wikidata; Q54931131
RX   PubMed=1358347;
RX   PubMed=11062746;
RX   PubMed=12137851;
CC   Population: Chinese; Taiwan.
CC   Doubling time: ~21 hours (Note=At 32th passage) (PubMed=1358347).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   70Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 29-06-23; Version: 6
CH   CVCL_RW30 ! NTUB1/As
CH   CVCL_RW31 ! NTUB1/P[14]
CH   CVCL_UN52 ! NTUB1/P[3]
CH   CVCL_UN53 ! NTUB1/P[9]
//
RX   PubMed=12137851; DOI=10.1016/S0090-4295(02)01699-0;
RA   Pu, Yeong-Shiau
RA   Hour, Tzyh-Chyuan
RA   Chen, Jun
RA   Huang, Chao-Yuan
RA   Guan, Jing-Yi
RA   Lu, Shiu-Hui
RT   "Cytotoxicity of arsenic trioxide to transitional carcinoma cells.";
RL   Urology 60:346-350(2002).
//
RX   PubMed=11062746;
RA   Hour, Tzyh-Chyuan
RA   Chen, Jun
RA   Huang, Chao-Yuan
RA   Guan, Jing-Yi
RA   Lu, Shiu-Hui
RA   Hsieh, Chang-Yao
RA   Pu, Yeong-Shiau
RT   "Characterization of chemoresistance mechanisms in a series of
RT   cisplatin-resistant transitional carcinoma cell lines.";
RL   Anticancer Res. 20:3221-3225(2000).
//
RX   PubMed=1358347;
RA   Yu, Hong-Jeng
RA   Tsai, Tsong-Chung
RA   Hsieh, Teh-Sheng
RA   Chiu, Tsu-Yih
RT   "Characterization of a newly established human bladder carcinoma cell
RT   line, NTUB1.";
RL   J. Formos. Med. Assoc. 91:608-613(1992).
//